Sage Appoints Geno Germano to Company s Board of Directors

Sage Appoints Geno Germano to Company s Board of Directors

CAMBRIDGE, Mass., July 19, 2016 Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat

life-altering central nervous system disorders, announced today that Geno Germano has been appointed to Sage s Board of Directors.

team is excited to welcome Mr. Germano to our Board, said Jeff Jonas, M.D., Chief Executive Officer of Sage. Mr. Germano s clear passion for creating medicines that significantly improve patients lives is a perfect fit

with Sage s vision and culture. Geno is an experienced and capable senior executive in the life sciences industry whose commercial expertise and experience in organizational scaling will be invaluable to Sage.

Geno Germano was recently appointed President of Intrexon, a leader in synthetic biology, effective June 1, 2016. As President, Mr. Germano is

responsible for leading Intrexon s management team and commercialization efforts utilizing the Company s technology platform for biologically-based solutions across a broad range of industries including Health, Consumer, Energy,

Environment and Food.

Mr. Germano has over 30 years of experience in the pharmaceutical industry and a consistent track record of improving

operating performance and increasing shareholder value across numerous leadership roles in multiple therapeutic categories and global markets at Pfizer, Wyeth and Johnson & Johnson. Prior to joining Intrexon, he was Group President of

Pfizer s Global Innovative Pharma Business, where he led a growing global $14 billion business with market-leading medicines and an extensive portfolio of late-stage development candidates in several therapeutic areas including cardiovascular,

metabolic disease, neuroscience, inflammation, immunology, and rare diseases. Mr. Germano was also Co-Chair of the Portfolio Strategy and Investment Committee focused on maximizing the return on research and development investment across the

Pfizer portfolio. Previously, Mr. Germano served as President and General Manager of Pfizer s Specialty Care and Oncology business units where he led commercial, medical, and post proof-of-concept pipeline strategy and development across

global markets, as well as held responsibility for driving P&L growth and pipeline value through disciplined portfolio management. In addition, while in this role he directed the integration of Wyeth and Pfizer Specialty Care and Vaccines

Businesses and developed top talent within the organization focusing on the leadership team.

Prior to joining Pfizer, Mr. Germano held numerous

executive and leadership roles at Wyeth Pharmaceuticals including President of Wyeth U.S., where he was responsible for delivery of operational results across four business units, as well as President of its Global Pharmaceutical and Women s

Healthcare Business. He is a member of the Group of Fifty (G50) and serves on the Board of the Biotechnology Innovation Organization, as well as on the Advisory Board of the Healthcare Businesswomen s Association and as a Trustee of the Albany

College of Pharmacy where he received his Bachelor of Science degree in Pharmacy.

About Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with

life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage s lead program, SAGE-547, is in Phase 3 clinical development for

super-refractory status epilepticus, a rare and severe seizure disorder, and is being developed for severe PPD. Sage is developing its next generation modulators, including SAGE-217, SAGE-689 and SAGE-718, with a focus on acute and chronic CNS

disorders. For more information, please visit www.sagerx.com.

Paul Cox, Sage Therapeutics

Maureen L. Suda, Suda Communications LLC